The KEYNOTE-028 reports an ORR of only 5.6% for PD-L1-positive vulvar cancer patients, whereas for vaginal cancer only a case series of two patients has been published to date, of which one responded and one progressed during pembrolizumab treatment [20,21]. This evidence concerns the gene CD274 and vulva cancer.